P23. Efficient ex vivo lysis of acute myeloid leukaemic (AML) cells mediated by triplebodies with dual-targeting capability in conjunction with natural killer cells as effectors

نویسندگان

  • G Fey
  • TA Braciak
  • S Wildenhain
  • CC Roskopf
  • C Schiller
  • N Fenn
  • IA Schubert
  • U Jacob
  • KP Hopfner
  • FS Oduncu
چکیده

Materials and methods Triplebodies are a new class of antibody derivatives developed by our team, which consist of 3 antigen-binding domains carried in a single polypeptide chain. The distal domains bind 2 targets on the same cancer cell, the central domain binds a trigger molecule on an effector cell. If the 2 targets on the cancer cell are different, the triplebody is said to be ‘dual-targeting’. The key new capability resulting from dual-targeting is the elimination of cancer cells with ‘increased selectivity’ (Schubert 2013; MAbs. PMID 24135631). Here the dual-targeting triplebody 33-16-123 (SPM-2) was developed and tested in redirected lysis assays in vitro. It carries binding domains for the surface antigens CD33 and CD123 on AML cells and for CD16, the Fc gamma RIII receptor on Natural Killer (NK) cells. This pair of target antigens is expressed on the blasts of a majority of AML patients and is present in increased surface density on AML-leukaemia stem cells (LSCs) relative to bulk AML cells and healthy hematopoietic stem cells. This combination offers the possibility of preferential targeting of AML-LSCs, and thus of minimal residual disease (MRD) cells. Human AML cell-lines and primary cells freshly drawn from AML patients were used in redirected lysis experiments. Target cells were labeled with Calcein AM. Effector cells were either ex vivo expanded mononuclear cells from healthy donors, or patient’s autologous NK cells enriched by immunomagnetic beads. Reactions proceeded for 4 hrs, and specific lysis was measured by release of fluorescent Calcein using an ELISA plate reader. Multicolor cytofluorimetry with fluorescent-labeled antibodies was used in addition to study elimination of subsets of AML cells.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Acute Myeloid Leukaemia in the Elderly

Treatment with anti-killer-cell immunoglobulin-like receptor (KIR) monoclonal antibody (mAb) is a new approach aimed at harnessing the antileukaemic potential of natural killer (NK) cells for the treatment of acute myeloid leukaemia (AML). NK cell antitumour activity is regulated by a balance between activating and inhibitory receptors (KIR). 1-7F9/IPH2101 is a fully human immunoglobulin G4 (Ig...

متن کامل

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

Antibody-based immunotherapy represents a promising strategy to eliminate chemorefractory leukemic cells in acute myeloid leukemia (AML). In this study, we evaluated a novel Fc-engineered antibody against CD157 (MEN1112) for its suitability as immunotherapy in AML. CD157 was expressed in 97% of primary AML patient samples. A significant, albeit lower expression level of CD157 was observed withi...

متن کامل

Selective Targeting of Human Lymphokine-Activated Killer Cells by CD3 Monoclonal Antibody Against the Interferon-Inducible High-Affinity Fcy RI Receptor (CD64) on Autologous Acute Myeloid Leukemic Blast Cells

The potential of the CD3 monoclonal antibody (MoAb) OKT3 to selectively target lymphokine-activated killer (LAK) cells and T-cell clones in vitro against autologous tumor cells was studied using material from patients with acute leukemias (1 9 acute myeloid leukemias [AML], and 3 acute lymphoblastic leukemias [ALL]). Cytotoxicity mediated by patient LAK cells against AML blasts, but not against...

متن کامل

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Acute myeloid leukemia (AML) is associated with a poor survival rate, and there is an urgent need for novel and more efficient therapies, ideally targeting AML stem cells that are essential for maintaining the disease. The interleukin 1 receptor accessory protein (IL1RAP; IL1R3) is expressed on candidate leukemic stem cells in the majority of AML patients, but not on normal hematopoietic stem c...

متن کامل

Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.

BACKGROUND AND OBJECTIVES Natural killer (NK) cells constitute an important area of research for hematologic malignancies. The anti-leukemic activity of NK cells against acute myeloid leukemia (AML) blasts has been described, but very few data are available for acute lymphoid leukemia (ALL). The present study was designed to investigate whether: (i) NK effectors could be expanded from adult and...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 2  شماره 

صفحات  -

تاریخ انتشار 2014